Edesa Biotech (EDSA)
(Delayed Data from NSDQ)
$4.55 USD
+0.03 (0.66%)
Updated May 17, 2024 03:55 PM ET
After-Market: $4.72 +0.17 (3.74%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Edesa Biotech, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 7 | 8 | 7 | 5 |
Receivables | 1 | 1 | 3 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 0 |
Total Current Assets | 6 | 9 | 12 | 8 | 6 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 9 | 12 | 15 | 11 | 6 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 1 | 2 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 2 | 2 | 0 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 2 | 0 |
Common Stock (Par) | 47 | 42 | 35 | 19 | 12 |
Capital Surplus | 13 | 11 | 5 | 2 | 0 |
Retained Earnings | -52 | -44 | -27 | -13 | -7 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | 9 | 13 | 9 | 5 |
Total Liabilities & Shareholder's Equity | 9 | 12 | 15 | 11 | 6 |
Total Common Equity | 7 | 9 | 13 | 7 | 5 |
Shares Outstanding | 3.00 | 2.20 | 1.80 | 1.30 | 1.00 |
Book Value Per Share | 2.35 | 4.27 | 7.26 | 5.10 | 5.26 |
Fiscal Year End for Edesa Biotech, Inc falls in the month of September.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,996 | 4 | 5 | 6 | 7 |
Receivables | 1 | 1 | 1 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 1 |
Total Current Assets | 4 | 5 | 6 | 7 | 8 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 6 | 8 | 9 | 9 | 11 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 1 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 2 | 2 | 2 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 47 | 47 | 47 | 46 | 45 |
Capital Surplus | 13 | 13 | 13 | 13 | 12 |
Retained Earnings | -56 | -54 | -52 | -51 | -49 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 4 | 6 | 7 | 8 | 9 |
Total Liabilities & Shareholder's Equity | 6 | 8 | 9 | 9 | 11 |
Total Common Equity | 100,003 | 6 | 7 | 8 | 9 |
Shares Outstanding | 3.10 | 3.10 | 3.00 | 2.90 | 2.80 |
Book Value Per Share | 32,259.14 | 1.88 | 2.35 | 2.71 | 3.21 |